CervoMed Inc. (CRVO) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. CervoMed Inc. is a clinical-stage biotechnology company developing neflamapimod, an oral small molecule targeting neuroinflammation for age-related brain disorders. The company's lead indication is Dementia with Lewy Bodies (DLB). The company operates as a single segment focused on clinical trials and nonclinical studies.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Grant Revenue | $0 | $0 | $3.7 million |
| Total Operating Expenses | $6.7 million | $14.8 million | $15.6 million |
| Net Loss | $(6.6) million | $(14.5) million | $(11.2) million |
| Cash & Marketable Securities | $24.9 million (as of June 30, 2026) | ||
| Accumulated Deficit | $112.2 million (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(14.9) million (YTD 2026) |
Material Changes vs. Prior Period
- Revenue Cessation: Grant revenue dropped to zero for the three and six months ended June 30, 2026, compared to $1.8 million and $3.7 million in the prior year periods. This is due to the completion of the RewinD-LB Trial and the exhaustion of the $21.3 million NIA Grant funding.
- Expense Reduction: Total operating expenses decreased by approximately 20% in Q2 2026 and 5% YTD 2026 compared to the prior year. This was driven primarily by a significant reduction in DLB-related clinical trial costs following the completion of the Phase 2b study.
- Capital Raising: In June 2026, the company completed two financing events:
- 2026 Private Placement: Raised ~$10.5 million gross proceeds.
- 2026 Registered Direct Offering: Raised ~$10.0 million gross proceeds.
- Share Count: Common stock outstanding increased from 9.25 million (Dec 31, 2025) to 13.53 million (June 30, 2026) due to the financings.
Outlook, Risks, and Management Commentary
- Liquidity Runway: Management believes the $24.9 million in cash and marketable securities as of June 30, 2026, is sufficient to fund operations through the third quarter of 2027.
- Strategic Focus: The company is prioritizing the establishment of a strategic partnership to advance neflamapimod into Phase 3 development for DLB. Operating expenses are expected to decline in the second half of 2026 as clinical activity winds down pending this partnership.
- Intellectual Property: Received a Notice of Allowance on June 16, 2026, for a patent protecting neflamapimod for DLB treatment (no AD co-pathology), extending protection to 2042.
- Regulatory Milestone: Announced on August 4, 2026, the receipt of an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway (ILAP) for DLB.
- Risks: The company has never been profitable and will require additional capital. Failure to secure a partnership or raise further capital could force delays or termination of development activities. A legal proceeding with a former CEO remains pending, though the trial date has been extended to October 2026.
Investor Verification Checklist
- Verify the status of the strategic partnership discussions for Phase 3 DLB development.
- Confirm the burn rate and cash runway assumptions given the cessation of NIA grant revenue.
- Review the terms of the June 2026 financings, specifically the warrant exercise prices ($3.14, $3.32, $5.00) and potential dilution.
- Monitor the outcome of the pending litigation (Paul Feller v. RestorGenex) scheduled for trial in October 2026.
- Assess the progress of the "Recovery After Stroke" and "nfvPPA" trials, which saw increased spending in Q2 2026.